Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcript
FTRE - Fortrea Holdings Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$18.57
DETAILS
HIGH:
$25.00
LOW:
$14.00
MEDIAN:
$19.00
CONSENSUS:
$18.57
UPSIDE:
40.47%
Stock News
Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Fortrea Reports First Quarter 2026 Results
Strong first-quarter performance reinforces confidence in FY 2026 guidance Book-to-bill of 1.15x is third consecutive quarter above 1.1x
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.
Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials
Highlights: Designed to transform clinical trial operations for sponsors, sites and study teams Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality Builds on Fortrea's flagship platform Xcellerate® to deliver near-real-time, role-based insights DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations.
SG Americas Securities LLC Raises Stock Holdings in Fortrea Holdings Inc. $FTRE
SG Americas Securities LLC lifted its holdings in shares of Fortrea Holdings Inc. (NASDAQ: FTRE) by 245.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,228 shares of the company's stock after purchasing an additional 108,925 shares during the
Assenagon Asset Management S.A. Lowers Stock Holdings in Fortrea Holdings Inc. $FTRE
Assenagon Asset Management S.A. lessened its position in Fortrea Holdings Inc. (NASDAQ: FTRE) by 57.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,779 shares of the company's stock after selling 157,445 shares during the quarter. Assenagon Asset Management S.A. owned approximately
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on March 10, 2026, to four newly hired employees. The award consisted of 130,000 RSUs that vest in three equal annual installments starting March 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.
Fortrea Holdings Inc. $FTRE Shares Sold by Citigroup Inc.
Citigroup Inc. trimmed its stake in Fortrea Holdings Inc. (NASDAQ: FTRE) by 49.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,470 shares of the company's stock after selling 290,848 shares during the period. Citigroup Inc. owned approximately 0.32% of
Allianz SE Buys Shares of 48,000 Fortrea Holdings Inc. $FTRE
Allianz SE purchased a new position in Fortrea Holdings Inc. (NASDAQ: FTRE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 48,000 shares of the company's stock, valued at approximately $404,000. Allianz SE owned approximately 0.05% of Fortrea as of its most recent SEC
Fortrea Holdings Inc. (FTRE) Q4 2025 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) Q4 2025 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago.
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets
Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Average Rating of “Hold” from Analysts
Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) has been assigned an average recommendation of "Hold" from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
FTRE or ACAD: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Price Targets
Fortrea price target raised to $14 from $11 at Deutsche Bank
$14.00
(was $16.14)
Justin Bowers
·
Deutsche Bank
Fortrea price target raised to $19 from $16 at Truist
$19.00
(was $15.15)
Truist Financial
Fortrea price target raised to $20 from $15 at Baird
$20.00
(was $14.53)
Robert W. Baird
Fortrea price target raised to $16 from $11 at Barclays
$16.00
(was $14.53)
Barclays
Fortrea price target lowered to $11 from $12 at Barclays
$11.00
(was $9.38)
Barclays
Fortrea price target raised to $19 from $15 at Baird
$19.00
(was $17.05)
Robert W. Baird
Fortrea price target raised to $15 from $13 at Mizuho
$15.00
(was $17.44)
Mizuho Securities
Fortrea upgraded to Buy from Hold at Truist
$22.00
(was $17.49)
Jailendra Singh
·
Truist Financial
Fortrea upgraded to Outperform from In Line at Evercore ISI
$25.00
(was $16.62)
Evercore ISI
Fortrea price target raised to $13 from $11 at Mizuho
$13.00
(was $16.19)
Ann Hynes
·
Mizuho Securities
Fortrea upgraded to Equal Weight from Underweight at Barclays
$15.00
(was $15.72)
Luke Sergott
·
Barclays
Citi Upgrades Fortrea (FTRE) to Buy
$21.00
(was $16.25)
Wedbush
Fortrea price target raised to $11 from $9 at Mizuho
$11.00
(was $10.70)
Ann Hynes
·
Mizuho Securities
Fortrea price target raised to $14 from $11 at Evercore ISI
$14.00
(was $11.25)
Elizabeth Anderson
·
Evercore ISI
Fortrea price target raised to $9 from $7 at Mizuho
$9.00
(was $9.52)
Mizuho Securities
Fortrea price target raised to $11 from $7 at Evercore ISI
$11.00
(was $9.31)
Elizabeth Anderson
·
Evercore ISI
Fortrea price target raised to $8 from $6 at Barclays
$8.00
(was $9.52)
Barclays
Fortrea price target raised to $14 from $9 at Baird
$14.00
(was $10.76)
Eric Coldwell
·
Robert W. Baird
Fortrea price target raised to $6 from $5 at Barclays
$6.00
(was $6.58)
Luke Sergott
·
Barclays
Fortrea price target lowered to $12 from $25 at Baird
$12.00
(was $10.96)
Robert W. Baird